Wintrust Investments’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
– Sell
-2,172
Closed -$206K – 480
2024
Q1
$206K Buy
+2,172
New +$202K 0.02% 446
2022
Q3
– Sell
-28,981
Closed -$2.15M – 406
2022
Q2
$2.15M Buy
+28,981
New +$2.18M 0.26% 69

Other funds holding XBI

Wintrust Investments's XBI Position: Q2 2024 in Review

Wintrust Investments sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2024, closing a stake of 2,172 shares — an estimated $206K sold.

Wintrust Investments first reported a position in XBI in Q2 2022 and held it in 2 quarters. The position peaked at $2.15M in Q2 2022. 762 funds tracked by Wall St. Rank hold XBI as of Q2 2024.

  • Wintrust Investments reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2024 after selling out during the quarter.
  • Wintrust Investments sold 2,172 State Street SPDR S&P Biotech ETF shares in Q2 2024, an estimated $206K.
  • Wintrust Investments first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and held it in 2 quarters.
  • Wintrust Investments's State Street SPDR S&P Biotech ETF position peaked at $2.15M in Q2 2022.
  • 762 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2024.

Based on Wintrust Investments's 13F filing for Q2 2024, filed 13 Aug 2024.